Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Unnatural Products is rewriting the rules for potent oral therapies.
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Empress Therapeutics is reverse-engineering microbial manufacturing.
Lab-grown ‘mini-colons’ enable the simulation of colorectal tumor dynamics and the high-resolution study of interactions with cells from the tumor’s native microenvironment. These next-generation organoids offer a wealth of new experimental opportunities, propelling the frontiers of cancer modeling in multiple directions.
We use a CRISPR screening platform based on adeno-associated virus and the Sleeping Beauty transposon (AAV-SB-CRISPR) to perform in vivo CRISPR screens in primary natural killer (NK) cells across four different tumor models, and identify calcium homeostasis modulator family member 2 (CALHM2) as an NK cellular checkpoint protein.
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Tenpoint Therapeutics optimizes delivery and generation of stem-cell-derived retinal cells for vision repair.
We developed SynTracker, a tool to track conspecific microbial strains using genome synteny. SynTracker is sensitive to genomic structural variation but not to single-nucleotide polymorphisms (SNPs). Combining SynTracker with methods for tracking strains using SNP profiles, we were able to detect species evolving by accumulating predominantly SNPs or predominantly structural variants.
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Tome Biosciences inserts large DNA sequences into precise genomic locations, overcoming limitations of base and prime editing.
